報價延遲最少15分鐘:2026/04/21 21:24 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
36.28 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
2.77/1.86
|
|
企業價值
6.15B
|
| 資產負債 |
|
每股賬面淨值
4.06
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
616.29M
|
|
每股收益
1.19
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, it has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. Its pipeline includes UBLITUXIMAB, SUB-Q UBLITUXIMAB, and AZER-CEL. Geographically, it generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from the international market. |
